A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)

UCB Pharma0 个研究点目标入组 729 人开始时间: 2005年4月最近更新: 2013年12月16日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: UCB Pharma
入组人数: 729
主要终点: Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

•At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.
•A skin test for grass pollens positive:
•Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.

•Have an associated asthma requiring corticosteroid treatment,
•Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,

Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment

Clinical efficacy over the first and over two weeks of treatment measured by symptoms (scored and individuals); Onset of action; Safety

发起方

申办方类型

Industry